| Factor Information | |
|---|---|
| Data ID | 322 |
| Factor | hematocrit level |
| Description | N/A |
| Biomarker | NA |
| Classification | E11 (physiological factor - physical sign) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | PAH-CHD patients |
| p Value | <0.001 |
| Conclusion | Both therapies were associated with improvement of hematocrit level. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 101 |
| CHD Type | isolated CHD |
| CHD Subtype | CHD with PAH |
| Reference | |
|---|---|
| PMID | 30343508 |
| Year | 2019 |
| Title | Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | Adolescents and adults | |
| Source | blood | |
| Region | Brazil, Sao Paulo | |
| Method | Student’s t test or the Mann- Whitney test | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Tadalafil group(6 months)(Treatment) | baseline(Control) |
| Number | 15 | 15 |
| Age | 10-54 years | 18-50 years |
| Gender (Male: Female) | 03:12:00.000 | 03:12:00.000 |
| Marker Level | 53(51-68) | 56(54-71) |
